



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chairman: **Andrew Davies**
Prif Weithredwr/Chief Executive: **Tracy Myhill**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 9th July 2019
Ein Cyf / Our Ref: 19-F-017

☎ 01639 683312

☎ 01639 648363

🖱 FOIA.Requests@wales.nhs.uk

Corporate Administration
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

[Redacted]

[Redacted]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 14th June 2019. Your request sought information relating to cancer treatments.

The information provided is for the period 01/12/2018 to 31/05/2019.

1. Does your Health Board treat adult multiple myeloma [MM]? - if you refer your multiple myeloma patients to another centre, please state which.

Yes

2. If yes, then how many MM patients, have been treated in the past 6 months with the following;

Bortezomib [Velcade]	<5
Carfilzomib [Kyprolis]	Nil
Ixazomib [Ninlaro]	Nil
Lenalidomide [Revlimid]	21
Daratumumab [Darzalex]	9
Melphalan, prednisolone & thalidomide (known as MPT)	Nil
Cyclophosphamide, thalidomide & dexamethasone (known as CTD)	<5
Pomalidomide [Imnovid]	19



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- 3. If you are able to split by therapy line for question 2, please indicate the number of patients above being treated, 1st line and 2nd line.**

This information is not held centrally on our systems.

- 4. Does your health board treat adult/paediatric primary immune thrombocytopenia patients [ITP] ? - if you refer your adult/paediatric primary immune thrombocytopenia patients to another centre, please state which.**

Adult only

- 5. If yes, then of the treated adult/paediatric primary immune thrombocytopenia patients, how many are on the following;**

Eltrombopag [Revolade]	This information is not held centrally on our systems.
Romiplostim [Nplate]	9

- 6. At what line of treatment would you currently use a Thrombopoietin Receptor Agonist [TPO] (Eltrombopag [Revolade], Romiplostim [Nplate]) in an immune thrombocytopenia purpura [ITP] patient.**

3rd line following failure of systemic steroids and rituximab

- 7. Do you treat patients with a Thrombopoietin Receptor Agonist TPO for the following diseases?**

- 7a. Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy**

Yes

- 7b. Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation**

Yes

- 7c. Chemotherapy induced thrombocytopenia (CIT)**

No

- 8. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?**

32 with Systemic Anti-Cancer Therapy (SACT)



9. If possible how many CLL patients treated were new to therapy in the past 3 months?

5 with SACT

10. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;

Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR)

Bendamustine and rituximab (known as BR) <5

Ibrutinib [Imbruvica] 8

Chlorambucil <5

Venetoclax <5

Obinutuzumab <5

Idelalisib <5

Fludarabine and rituximab (known as FR) <5

High-dose prednisone and rituximab 5

Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) Nil

Alemtuzumab (Campath) with rituximab Nil

Please note the numbers above will include patients who were part of clinical trials.

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.



Yours sincerely

A handwritten signature in black ink that reads "P. a. wenger". The signature is written in a cursive, slightly slanted style.

Pam Wenger
Director of Corporate Governance

